(Q53588316)

15 May 2018

title

Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. (English)

1 reference

15 May 2018

0 references

0 references

1 reference

0 references

1 reference

1

Firdausi Qadri

1 reference

15 May 2018

14

David A Sack

1 reference

15 May 2018

13

John D Clemens

1 reference

15 May 2018

Shah M. Faruque

3

Shah M Faruque

1 reference

15 May 2018

Mohammed Abdus Salam

4

Mohammed A Salam

1 reference

15 May 2018

Mohiul Islam Chowdhury

2

Mohiul I Chowdhury

1 reference

15 May 2018

Abdullah Tarique

8

Abdullah Al Tarique

1 reference

15 May 2018

Lorenz von Seidlein

9

Lorenz V Seidlein

1 reference

15 May 2018

Kevin P Killeen

11

Kevin P Killeen

1 reference

15 May 2018

author name string

Tanvir Ahmed

5

1 reference

15 May 2018

Yasmin A Begum

6

1 reference

15 May 2018

Amit Saha

7

1 reference

15 May 2018

Eunsik Park

10

1 reference

15 May 2018

John J Mekalanos

12

1 reference

15 May 2018

PXV Study Group

15

1 reference

15 May 2018

language of work or name

English

0 references

publication date

5 September 2006

1 reference

15 May 2018

number of pages

8

1 reference

inferred from page(s)

published in

Vaccine

1 reference

15 May 2018

volume

25

1 reference

15 May 2018

issue

2

1 reference

15 May 2018

page(s)

231-238

1 reference

15 May 2018

Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18–36 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Selection for in vivo regulators of bacterial virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Predisposition for cholera of individuals with O blood group. Possible evolutionary significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

7 January 2021

Induction of the lysogenic phage encoding cholera toxin in naturally occurring strains of toxigenic Vibrio cholerae O1 and O139.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

7 January 2021

Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

7 January 2021

Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

7 January 2021

Weak serum and intestinal antibody responses to Vibrio cholerae soluble hemagglutinin in cholera patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.031

7 January 2021

10.1016/J.VACCINE.2006.08.031

Identifiers

DOI

1 reference

15 May 2018

PubMed ID

16996172

1 reference

15 May 2018